Janssen Logo 1 captis executive search management consulting leadership board services

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022

This is not a CAPTIS article. Originally, it was published here.